Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)

被引：13
|
作者：
Zboralski, D. [1 ]
Osterkamp, F. [2 ]
Simmons, A. D. [3 ]
Bredenbeck, A. [4 ]
Schumann, A. [4 ]
Paschke, M. [5 ]
Beindorff, N. [6 ]
Mohan, A-M. [7 ]
Nguyen, M. [3 ]
Xiao, J. [8 ,9 ]
Harding, T. C. [3 ]
Hoehne, A. [10 ]
Reineke, U. [11 ]
Smerling, C. [12 ]
机构：
[1] 3B Pharmaceut GmbH, Assay Unit, Berlin, Germany
[2] 3B Pharmaceut GmbH, Chem & Analyt, Berlin, Germany
[3] Clovis Oncol Inc, Translat Med, Boulder, CO USA
[4] 3B Pharmaceut GmbH, Nucl Med, Berlin, Germany
[5] 3B Pharmaceut GmbH, Biol & Assay Dev, Berlin, Germany
[6] Charite Univ Med Berlin, Berlin Expt Radionuclide Imaging Ctr BERIC, Berlin, Germany
[7] Charite Univ Med Berlin, Dept Nucl Med, Berlin, Germany
[8] Clovis Oncol Inc, Clin Pharmacol, Boulder, CO USA
[9] Clovis Oncol Inc, DMPK, Boulder, CO USA
[10] 3B Pharmaceut GmbH, Radiopharmaceut Technol, Berlin, Germany
[11] 3B Pharmaceut GmbH, Berlin, Germany
[12] 3B Pharmaceut GmbH, Nucl Med & Imaging, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.685
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
571P
引用
收藏
页码：S488 / S488
页数：1
相关论文
共 50 条
  • [31] Synthesis and evaluation of a fluorinated PET imaging probe targeting fibroblast activation protein (FAP)
    Filippi, Nicolo
    Van Rymenant, Yentl
    Cianni, Lorenzo
    Stroobants, Sigrid
    De Meester, Ingrid
    Van der Veken, Pieter
    Elvas, Filipe
    NUCLEAR MEDICINE AND BIOLOGY, 2023, 126 : S154 - S155
  • [32] Fibroblast Activation Protein Alpha (FAPα) in Fibrosis: Beyond a Perspective Marker for Activated Stromal Cells?
    Basalova, Nataliya
    Alexandrushkina, Natalya
    Grigorieva, Olga
    Kulebyakina, Maria
    Efimenko, Anastasia
    BIOMOLECULES, 2023, 13 (12)
  • [33] Preclinical evaluation and first-in-human imaging of [203/212Pb]Pb-PSV359, a novel cyclic peptide targeting fibroblast activation protein-alpha (FAP)
    Cagle, B.
    Baumhover, N. J.
    Thakral, P.
    Malik, D.
    Vance, I. N.
    Liu, D.
    Rodman, S. N.
    Kalen, A. L.
    Kapoor, S.
    Sagastume, E. A.
    Johnson, F. L.
    Schultz, M. K.
    Sen, I. B.
    Li, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S227 - S227
  • [34] Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
    Bughda, Reyisa
    Dimou, Paraskevi
    D'Souza, Reena R.
    Klampatsa, Astero
    IMMUNOTARGETS AND THERAPY, 2021, 10 : 313 - 323
  • [35] Design, Synthesis and Preclinical Assessment of 99mTc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging
    Trujillo-Benitez, Diana
    Luna-Gutierrez, Myrna
    Ferro-Flores, Guillermina
    Ocampo-Garcia, Blanca
    Santos-Cuevas, Clara
    Bravo-Villegas, Gerardo
    Morales-Avila, Enrique
    Cruz-Nova, Pedro
    Diaz-Nieto, Lorenza
    Garcia-Quiroz, Janice
    Azorin-Vega, Erika
    Rosato, Antonio
    Melendez-Alafort, Laura
    MOLECULES, 2022, 27 (01):
  • [36] Combination of Fibroblast Activation Protein (FAP)targeted Radioligand Therapy with Anti-PD-L1 immunotherapy and Anti-VEGF Therapy
    Zhao, T.
    Zhao, L.
    Pang, Y.
    Jakobsson, V.
    Baum, R. P.
    Chen, X.
    Zhang, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S314 - S314
  • [37] Peptide targeted radioligand therapy (PTRT) using Fibroblast Activation Protein (FAP) labelled with 225Actinium as mono- or TANDEM-therapy: A retrospective analysis of long-term safety and survival in patients with progressive, end-stage malignancies
    Perrone, E.
    Mishra, A.
    Eismant, A.
    Ghai, K.
    Greifenstein, L.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S35 - S35
  • [38] A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    Twelves, C. J.
    Banerji, U.
    Tap, W. D.
    Cook, N.
    Evans, T. R. J.
    Plummer, R.
    Anthoney, A.
    Plummer, C.
    Dawson, R.
    Loadman, P.
    Lahu, G.
    Jones, H.
    Kinnersley, N.
    Edwards, R.
    Gordon, G.
    Cranmer, L. D.
    ANNALS OF ONCOLOGY, 2024, 35 : S511 - S511
  • [39] A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    Banerji, Udai
    Cook, Natalie
    Anthoney, Alan
    Plummer, Ruth
    Tap, William D.
    Evans, Jeffry T.
    Cranmer, Lee D.
    Plummer, Christopher
    Loadman, Paul
    Lahu, Gezim
    Jones, Huw S.
    Kinnersley, Nelson
    McLaughlin, Fiona
    Twelves, Chris
    CANCER RESEARCH, 2024, 84 (07)
  • [40] 177Lu-DOTA-EB-FAPI Imaging and Therapy of Fibroblast Activation Protein (FAP) Positive Tumors
    Wen, Xuejun
    Xu, Pengfei
    Shi, Mengqi
    Guo, Zhide
    Zhang, Xianzhong
    Khong, Pek-Lan
    Zhang, Jingjing
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
12345